Litfulo

ritlecitinib · Pfizer Europe MA EEIG
AUTHORISED IN THE EU

What Litfulo is used for

Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Litfulo
Active substance
ritlecitinib
Disease area
Alopecia Areata
Medicine group
Immunosuppressants
ATC code
L04AF08
Marketing authorisation holder
Pfizer Europe MA EEIG
Authorised in the EU since
2023

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Litfulo used for?

Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

What is the active substance in Litfulo?

Litfulo contains ritlecitinib.

Who makes Litfulo?

The EU marketing authorisation holder is Pfizer Europe MA EEIG.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.